Effects and Mechanisms of Luteolin, a Plant-Based Flavonoid, in the Prevention of Cancers Via Modulation of Inflammation and Cell Signaling Molecules

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Mar 13

PMID 38474604

Authors

Saleh A Almatroodi

Ahmad Almatroudi

Hajed Obaid A Alharbi

Amjad Ali Khan

Arshad Husain Rahmani

Affiliations

Soon will be listed here.

Abstract

Luteolin, a flavonoid, is mainly found in various vegetables and fruits, including carrots, cabbages, onions, parsley, apples, broccoli, and peppers. Extensive research in vivo and in vitro has been performed to explore its role in disease prevention and treatment. Moreover, this compound possesses the ability to combat cancer by modulating cell-signaling pathways across various types of cancer. The studies have confirmed that luteolin can inhibit cancer-cell survival and proliferation, angiogenesis, invasion, metastasis, mTOR/PI3K/Akt, STAT3, Wnt/β-catenin, and cell-cycle arrest, and induce apoptosis. Further, scientific evidence describes that this compound plays a vital role in the up/down-regulation of microRNAs (miRNAs) in cancer therapy. This review aims to outline the anti-cancer mechanisms of this compound and its molecular targets. However, a knowledge gap remains regarding the studies on its safety and efficacy and clinical trials. Therefore, it is essential to conduct more research based on safety, efficacy, and clinical trials to explore the beneficial role of this compound in disease management, including cancer.

Citing Articles

Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.

Lv J, Song X, Luo Z, Huang D, Xiao L, Zou K Front Pharmacol. 2025; 16:1535555.

PMID: 40012626 PMC: 11861102. DOI: 10.3389/fphar.2025.1535555.

Phytochemical Profile and Anticancer Potential of Extracts on Glioblastoma, Bladder Cancer, and Breast Cancer Cells.

Nalkiran I, Sevim Nalkiran H Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005959 PMC: 11859872. DOI: 10.3390/ph18020144.

Telomerase in cancer- ongoing quest and future discoveries.

Mishra A, Patel T Mol Biol Rep. 2025; 52(1):161.

PMID: 39862360 DOI: 10.1007/s11033-025-10251-6.

Effects of Luteolin Treatment on Postharvest Quality and Antioxidant Capacity of Nanfeng Tangerines.

Dong W, Wang X, Xiang M, Chen J, Zeng J, Chen M Foods. 2025; 14(1.

PMID: 39796358 PMC: 11719979. DOI: 10.3390/foods14010068.

Anti-Graying Effects of External and Internal Treatments with Luteolin on Hair in Model Mice.

Iida M, Kagawa T, Yajima I, Harusato A, Tazaki A, Nishadhi D Antioxidants (Basel). 2025; 13(12.

PMID: 39765877 PMC: 11673595. DOI: 10.3390/antiox13121549.

References

Eferl R, Wagner E . AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003; 3(11):859-68. DOI: 10.1038/nrc1209. View

Kollur S, Prasad S, Pradeep S, Veerapur R, Patil S, Amachawadi R . Luteolin-Fabricated ZnO Nanostructures Showed PLK-1 Mediated Anti-Breast Cancer Activity. Biomolecules. 2021; 11(3). PMC: 7998981. DOI: 10.3390/biom11030385. View

Shi M, Chen Y, Liao H . Effect of luteolin on apoptosis and vascular endothelial growth factor in human choroidal melanoma cells. Int J Ophthalmol. 2021; 14(2):186-193. PMC: 7840359. DOI: 10.18240/ijo.2021.02.02. View

Yasuda M, Fujita K, Hosoya T, Imai S, Shimoi K . Absorption and Metabolism of Luteolin and Its Glycosides from the Extract of Chrysanthemum morifolium Flowers in Rats and Caco-2 Cells. J Agric Food Chem. 2015; 63(35):7693-9. DOI: 10.1021/acs.jafc.5b00232. View

Ou-Yang S, Lu J, Kong X, Liang Z, Luo C, Jiang H . Computational drug discovery. Acta Pharmacol Sin. 2012; 33(9):1131-40. PMC: 4003107. DOI: 10.1038/aps.2012.109. View

Zhang C, Huang T, Wu B, He W, Liu D . Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017; 8(43):75756-75766. PMC: 5650462. DOI: 10.18632/oncotarget.20798. View

Takahashi T, Kobori M, Shinmoto H, Tsushida T . Structure-activity relationships of flavonoids and the induction of granulocytic- or monocytic-differentiation in HL60 human myeloid leukemia cells. Biosci Biotechnol Biochem. 1999; 62(11):2199-204. DOI: 10.1271/bbb.62.2199. View

Lu X, Li Y, Li X, Aisa H . Luteolin induces apoptosis through suppressing the MAPK and PI3K signaling pathways in gastric cancer. Oncol Lett. 2017; 14(2):1993-2000. PMC: 5530081. DOI: 10.3892/ol.2017.6380. View

Kang K, Piao M, Hyun Y, Zhen A, Cho S, Ahn M . Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells. Exp Mol Med. 2019; 51(4):1-14. PMC: 6465248. DOI: 10.1038/s12276-019-0238-y. View

10.

Rehan M . Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches. PLoS One. 2019; 14(6):e0219180. PMC: 6597235. DOI: 10.1371/journal.pone.0219180. View

11.

Liu Y, Zheng C, Huang Y, He M, Xu W, Li B . Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020). 2021; 2(3):315-340. PMC: 8554658. DOI: 10.1002/mco2.55. View

12.

Chang H, Mi M, Gu Y, Yuan J, Ling W, Lin H . [Effects of flavonoids with different structures on proliferation of leukemia cell line HL-60]. Ai Zheng. 2007; 26(12):1309-14. View

13.

ElShamy W, Sinha A, Said N . Aggressiveness Niche: Can It Be the Foster Ground for Cancer Metastasis Precursors?. Stem Cells Int. 2016; 2016:4829106. PMC: 4963571. DOI: 10.1155/2016/4829106. View

14.

Yao Y, Rao C, Zheng G, Wang S . Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR‑384/pleiotrophin axis. Oncol Rep. 2019; 42(1):131-141. PMC: 6549074. DOI: 10.3892/or.2019.7136. View

15.

Fu G, Brkic J, Hayder H, Peng C . MicroRNAs in Human Placental Development and Pregnancy Complications. Int J Mol Sci. 2013; 14(3):5519-44. PMC: 3634453. DOI: 10.3390/ijms14035519. View

16.

Galluzzi L, Pietrocola F, Bravo-San Pedro J, Amaravadi R, Baehrecke E, Cecconi F . Autophagy in malignant transformation and cancer progression. EMBO J. 2015; 34(7):856-80. PMC: 4388596. DOI: 10.15252/embj.201490784. View

17.

Sabzichi M, Hamishehkar H, Ramezani F, Sharifi S, Tabasinezhad M, Pirouzpanah M . Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev. 2014; 15(13):5311-6. DOI: 10.7314/apjcp.2014.15.13.5311. View

18.

Larvol B, Wilkerson L . In silico drug discovery: tools for bridging the NCE gap. Nat Biotechnol. 1998; 16 Suppl:33-4. DOI: 10.1038/5412. View

19.

Wang L, Chen Q, Zhu L, Li Q, Zeng X, Lu L . Metabolic Disposition of Luteolin Is Mediated by the Interplay of UDP-Glucuronosyltransferases and Catechol-O-Methyltransferases in Rats. Drug Metab Dispos. 2016; 45(3):306-315. PMC: 6041822. DOI: 10.1124/dmd.116.073619. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View